Binimetinib

證據等級: L5

預測適應症: 10 個

Binimetinib: From BRAF V600E/K Mutant Melanoma to Choroideremia

One-Sentence Summary

Binimetinib is a MEK1/2 kinase inhibitor approved for use in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma harboring BRAF V600E/K mutations. The TxGNN model predicts it may be effective for Choroideremia with a prediction score of 98.63%, however, there are currently no clinical trials and no publications supporting this direction, placing the evidence at Level 5 (AI model prediction only).

Quick Overview

Item	Content
Original Indication	BRAF V600E/K mutation-positive unresectable or metastatic melanoma (in combination with encorafenib)
Predicted New Indication	Choroideremia
TxGNN Prediction Score	98.63%
Evidence Level	L5
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known clinical information, Binimetinib is a selective inhibitor of MEK1 and MEK2 kinases — components of the RAS/MAPK (Rapidly Accelerated Fibrosarcoma/Mitogen-Activated Protein Kinase) signaling cascade. It is used in combination with the BRAF inhibitor encorafenib to suppress downstream ERK phosphorylation, thereby halting tumor cell proliferation in BRAF V600-mutant melanoma.

Choroideremia is an X-linked recessive hereditary retinal dystrophy caused by loss-of-function mutations in the CHM gene, which encodes Rab Escort Protein 1 (REP1). The disease mechanism centers on impaired Rab geranylgeranyl transferase (Rab-GGTase) activity, leading to failure of intracellular vesicular transport in retinal pigment epithelium and photoreceptors, and their subsequent progressive degeneration. This pathophysiology does not have a direct, established connection to the MEK-ERK signaling axis.

The high TxGNN prediction score likely reflects a distant, indirect association in the knowledge graph — possibly through shared retinal cell survival nodes — rather than a specific mechanistic link. Without preclinical experimental evidence demonstrating MEK-ERK pathway involvement in choroideremia pathophysiology, this prediction cannot be mechanistically justified at this time, and the biological rationale requires foundational research before any clinical translation is considered.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

Binimetinib currently holds no marketing authorization in Taiwan. The drug is not marketed domestically.

Cytotoxicity

Binimetinib’s original approved indication is unresectable or metastatic melanoma — a malignancy — and it belongs to the kinase inhibitor class of anticancer agents.

Item	Content
Cytotoxicity Classification	Targeted therapy — MEK1/2 inhibitor (non-conventional cytotoxic; not a classical alkylating or antimetabolite agent)
Myelosuppression Risk	Low (MEK inhibitors carry substantially lower myelosuppression risk than conventional chemotherapy; anaemia and neutropenia reported at low frequency)
Emetogenicity Classification	Low
Monitoring Items	CBC with differential (baseline and periodic), liver function tests (ALT/AST/bilirubin), cardiac function (LVEF by echocardiography), serum creatine kinase (CK), ophthalmological examination (retinal vein occlusion, uveitis, serous retinopathy), blood pressure
Handling Protection	Please refer to the SmPC warnings and precautions; standard oral anticancer drug handling precautions apply per institutional protocol

Safety Considerations

Please refer to the SmPC for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score (98.63%), the mechanistic rationale for applying a MEK inhibitor to choroideremia — a disease driven by CHM gene mutation and Rab-GGTase pathway dysfunction — is absent, and no supporting clinical trials or published literature exist. There is no basis to advance this candidate without primary mechanistic evidence.

To proceed, the following is needed:

Basic mechanistic research to determine whether MEK-ERK pathway activity contributes to choroideremia pathophysiology or photoreceptor survival
Preclinical validation using CHM-knockout animal models or patient-derived retinal organoids treated with binimetinib
TFDA prescribing information (SmPC equivalent) to fully characterize the safety profile for potential new patient populations, including ophthalmic considerations
Detailed MOA data from DrugBank or peer-reviewed sources to enable formal mechanistic linkage analysis
Landscape review of the choroideremia treatment pipeline (note: CHM gene replacement therapy via AAV vector is the leading clinical approach and represents a fundamentally different mechanism; the competitive and scientific context must be assessed before committing resources to a small-molecule repurposing strategy)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.